Podcast: Biosimilar Development - - BioPharm International

ADVERTISEMENT

Podcast: Biosimilar Development


blog comments powered by Disqus


Anjan Selz, cofounder and CEO of Finox Biotech, takes us on the exciting journey from cell bank to Phase III, something that was achieved in just four years for his company’s biosimilar product, Afolia. In this first of three podcasts, Selz notes that Finox Biotech decided very early on that it wanted to move away from the “me too” approach to biosimilars and focus on product differentiation. Selz goes into detail about biosimilar candidate selection using Afolia (a follicle stimulating hormone), as an example, and describes the importance of having a good understanding of the patent landscape. Selz describes Finox’s outsourcing strategies in terms of partner selection—notably, all are based in Western Europe, and also offers insight into creating meaningful relationships in which success is a shared goal. Posted Dec. 2011.

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here